Zylox Tonbridge Medical Technology (SEHK:2190) Margin Jump Reinforces Bullish Community Narratives

Simply Wall St.03-18

Zylox-Tonbridge Medical Technology (SEHK:2190) has reported first half FY 2025 results with revenue of C¥482 million and basic EPS of C¥0.38, against a backdrop of trailing twelve month EPS of C¥0.76 ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620268899?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","is_english":true,"pubTime":"2026-03-18 21:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620268899","market":"us","top_or_hot":-1,"title":"Zylox Tonbridge Medical Technology (SEHK:2190) Margin Jump Reinforces Bullish Community Narratives","media":"Simply Wall St.","content":"<div>\n<p>Zylox-Tonbridge Medical Technology (SEHK:2190) has reported first half FY 2025 results with revenue of C¥482 million and basic EPS of C¥0.38, against a backdrop of trailing twelve month EPS of C¥0.76 ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/healthcare/hkg-2190/zylox-tonbridge-medical-technology-shares/news/zylox-tonbridge-medical-technology-sehk2190-margin-jump-rein\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zylox Tonbridge Medical Technology (SEHK:2190) Margin Jump Reinforces Bullish Community Narratives</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZylox Tonbridge Medical Technology (SEHK:2190) Margin Jump Reinforces Bullish Community Narratives\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-18 21:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/healthcare/hkg-2190/zylox-tonbridge-medical-technology-shares/news/zylox-tonbridge-medical-technology-sehk2190-margin-jump-rein><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Zylox-Tonbridge Medical Technology (SEHK:2190) has reported first half FY 2025 results with revenue of C¥482 million and basic EPS of C¥0.38, against a backdrop of trailing twelve month EPS of C¥0.76 ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/healthcare/hkg-2190/zylox-tonbridge-medical-technology-shares/news/zylox-tonbridge-medical-technology-sehk2190-margin-jump-rein\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"https://simplywall.st/stocks/hk/healthcare/hkg-2190/zylox-tonbridge-medical-technology-shares/news/zylox-tonbridge-medical-technology-sehk2190-margin-jump-rein","article_id":"2620268899","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/healthcare/hkg-2190/zylox-tonbridge-medical-technology-shares/news/zylox-tonbridge-medical-technology-sehk2190-margin-jump-rein","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2620268899","pubTimestamp":1773839197,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Zylox-Tonbridge Medical Technology (SEHK:2190) has reported first half FY 2025 results with revenue of C¥482 million and basic EPS of C¥0.38, against a backdrop of trailing twelve month EPS of C¥0.76 and revenue of about C¥1.1 billion that has been associated with earnings growth of 143.7% year over year. Over recent periods the company has seen revenue move from C¥366 million in 1H 2024 to C¥416 million in 2H 2024 and then to C¥482 million in 1H 2025, while basic EPS shifted from C¥0.21 to...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1583":"高瓴概念","BLSG":"2倍做多BLSH ETF-Leverage Shares","BK4112":"金融交易所和数据","BK1574":"生物医药B类股","BLSX":"Tradr 2X Long BLSH Daily ETF","BK1100":"医疗保健设备","02190":"归创通桥","BK1587":"次新股"},"translate_title":"Zylox Tonbridge Medical Technology(SEHK：2190)利润率跃升强化了看涨的社区叙事","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BLSX":0.6,"02190":1.98,"BLSG":0.6},"content_text":"Zylox-Tonbridge Medical Technology (SEHK:2190) has reported first half FY 2025 results with revenue of C¥482 million and basic EPS of C¥0.38, against a backdrop of trailing twelve month EPS of C¥0.76 and revenue of about C¥1.1 billion that has been associated with earnings growth of 143.7% year over year. Over recent periods the company has seen revenue move from C¥366 million in 1H 2024 to C¥416 million in 2H 2024 and then to C¥482 million in 1H 2025, while basic EPS shifted from C¥0.21 to C¥0.10 and then to C¥0.38, setting up a results season in which expanding margins and higher profitability are central to the story investors are reacting to. See our full analysis for Zylox-Tonbridge Medical Technology. With the latest figures on the table, the next step is to compare these results with the dominant narratives around Zylox-Tonbridge Medical Technology to see which views are supported by the numbers and which might need a rethink. Curious how numbers become stories that shape markets? Explore Community Narratives SEHK:2190 Earnings & Revenue History as at Mar 2026 AdvertisementMargins Backed By 23.1% Net Profit Level  Over the last 12 months, Zylox-Tonbridge Medical Technology reported a net profit margin of 23.1%, compared with 12.8% in the prior year period, alongside trailing twelve month net income of C¥244.37 million on revenue of C¥1.06b. What stands out for a bullish view is that this higher margin sits on top of trailing twelve month earnings growth of 143.7% and a reported five year annualized earnings growth rate of 60.7%. This supports the idea of a business that has been turning more of its C¥1.06b in revenue into profit, even though any future margin path will still depend on how costs and pricing develop.  Revenue Trend Supports 18.4% Growth Profile  On a half year basis, revenue moved from C¥365.99 million in 1H 2024 to C¥416.49 million in 2H 2024 and then to C¥481.97 million in 1H 2025, while over the last 12 months revenue is reported at C¥1.06b with an annual growth rate of 18.4%. Supporters with a bullish stance point to this combination of reported 18.4% revenue growth and 23.5% forecast earnings growth per year over the next three years as a sign that recent top line momentum and earnings expansion are working together. At the same time, the step from C¥365.99 million to C¥481.97 million over the last three half year periods also shows how sensitive the story is to keeping that pace up across future reporting periods.  Strong top line growth paired with margin expansion is exactly the kind of pattern bullish investors watch for when they build a longer term story around a business like this, and that is where the broader community discussion can help you see how others are joining the dots between these figures and their own expectations for Zylox-Tonbridge Medical Technology. 📊 Read the what the Community is saying about Zylox-Tonbridge Medical Technology. P/E Of 26.7x Sits Between Peers And Industry  The current trailing P/E of 26.7x sits below the peer group average of 40.3x but above the Hong Kong Medical Equipment industry average of 16.1x, while the DCF fair value of HK$32.46 and analyst price target of HK$30.25 are both above the current share price of HK$22.04. Investors who take a bullish angle see some support in the fact that the share price is about 32.1% below the DCF fair value of HK$32.46 and below the HK$30.25 analyst price target. At the same time, the higher P/E compared with the industry average of 16.1x creates a tension between viewing the stock as inexpensive relative to its growth profile and recognizing that the market is still pricing it above the wider industry on earnings.  Next Steps Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Zylox-Tonbridge Medical Technology's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move. If this mix of strong recent figures and optimistic narratives has you interested, take a moment to check the details yourself and decide where you stand, then look at the 4 key rewards See What Else Is Out There While earnings and margins have been strong, the P/E of 26.7x sitting above the wider industry and below peers highlights valuation tension around Zylox-Tonbridge Medical Technology. If that valuation gap makes you cautious, use the 228 high quality undervalued stocks to quickly spot other companies where current prices look more aligned with fundamentals and potential upside.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Zylox-Tonbridge Medical Technology might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620268899","isCrawlerRequest":true}